Are you one of the many struggling with unbearable nausea and vomiting from weight loss drugs like Wegovy? You're not alone, and there's potentially groundbreaking news on the horizon. Vanda Pharmaceuticals just announced stunningly positive results for their drug, Tradipitant, in preventing these debilitating side effects. This could be a game-changer, especially considering the booming $50 billion-plus market for GLP-1 agonists. Let's dive into what this means for you.
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) has revealed that Tradipitant, an oral neurokinin-1 (NK-1) receptor antagonist, has shown remarkable success in a recent clinical study. The study (VP-VLY-686-2601) specifically targeted the prevention of nausea and vomiting induced by Wegovy®, a GLP-1 receptor agonist commonly prescribed to overweight and obese adults. For those unfamiliar, GLP-1 agonists work by mimicking a natural hormone in your body, helping to regulate blood sugar and suppress appetite. However, a significant hurdle with these medications is the high incidence of nausea and vomiting, often leading patients to discontinue treatment.
The study design was straightforward yet impactful. Participants were pre-treated with either Tradipitant or a placebo before receiving a 1 mg injection of Wegovy®. Now, here's a crucial detail: 1 mg is a dose that typically requires nine weeks of gradual increase ('titration') to reach, minimizing side effects. By administering this dose immediately, the study aimed to really test Tradipitant's ability to combat nausea and vomiting. And the results? They were compelling.
The primary endpoint of the study was the proportion of participants experiencing vomiting. In the Tradipitant group, only 29.3% (17 out of 58) vomited, compared to a staggering 58.6% (34 out of 58) in the placebo group. That's a 50% relative reduction! But the good news doesn't stop there.
The study also met its key secondary endpoint: the proportion of participants experiencing both vomiting and significant nausea (defined as a nausea score of 3 or higher on a 0-5 scale). Only 22.4% of the Tradipitant group (13/58) experienced this, compared to 48.3% of the placebo group (28/58). Again, a statistically significant and clinically meaningful difference. Furthermore, Tradipitant maintained a consistent and favorable safety profile throughout the study, aligning with findings from previous trials, and didn't present any new safety concerns.
Here's a quick breakdown of the key numbers:
| Endpoint | Placebo (N=58) | Tradipitant (N=58) | P-value |
|-----------------------------------------------|----------------|--------------------|---------|
| Proportion with vomiting* | 58.6% (34/58) | 29.3% (17/58) | 0.0016 |
| Proportion with vomiting and worst nausea ≥3** | 48.3% (28/58) | 22.4% (13/58) | 0.0039 |
Primary endpoint
*Key secondary endpoint, nausea of >= 3 denotes moderate or worse on a 0-5 point scale of severity
Mihael H. Polymeropoulos, M.D., President, CEO, and Chairman of Vanda, emphasized the significance of these results. "These results demonstrate tradipitant's potential to mitigate GLP-1 induced nausea and vomiting which are key contributors of the 30-50% real-world discontinuation rates for GLP-1 agonists, often before therapeutic doses are reached," he stated. He further added that Tradipitant could significantly improve patient adherence, allowing more individuals to reap the full therapeutic benefits of these medications. This, of course, assumes that patients are discontinuing solely due to nausea/vomiting, which is a point worth considering. Could other factors contribute to the high discontinuation rates?
And this is the part most people miss... the efficacy observed in this study aligns with Tradipitant's previous performance in treating motion sickness. In fact, multiple studies involving over 800 individuals showed that Tradipitant reduced vomiting by more than 50% in randomized controlled trials. This positions Tradipitant as a potentially transformative addition to the rapidly growing GLP-1 agonist market. The potential market impact is huge, with the GLP-1 agonist market currently exceeding $50 billion in the first nine months of 2025 alone.
But here's where it gets controversial... Some might argue that focusing solely on mitigating side effects doesn't address the root cause of obesity and related health issues. Are we simply masking problems instead of promoting long-term lifestyle changes? It's a valid point to consider.
Early discontinuations of GLP-1 agonists due to gastrointestinal side effects result in significant financial and health-related burdens. Patients miss out on substantial weight loss (15-20% with sustained use) and reductions in complications like diabetes progression and cardiovascular events. Payors, on the other hand, face wasted spending on unused prescriptions and the ongoing costs associated with unmanaged obesity, including hospitalizations.
The clinical trial involved 116 healthy overweight or obese adults (BMI 25–40 kg/m²) who had no prior experience with GLP-1 agonists. Participants received a 1 mg injection of Wegovy® after being pretreated with either Tradipitant 85 mg twice daily or a placebo for one week, followed by another week of continued treatment post-dosing. The study outcomes were measured using daily patient-reported assessments.
Vanda plans to pursue an efficient development path to obtain regulatory approval for Tradipitant to address this unmet medical need. A Phase III program is expected to begin in the first half of 2026, potentially solidifying Tradipitant as a crucial adjunct therapy to enhance outcomes in GLP-1 agonist treatments.
References
- Blue Health Intelligence. (2024, May). Real-world trends inGLP-1 treatment persistence and prescribing for weight management [Issue brief]. Blue Cross Blue Shield Association. https://www.bcbs.com/media/pdf/BHIIssueBriefGLP1Trends.pdf
- Samuels JM, Ye F, Irlmeier R, Silver H, Srivastava G, Spann M. Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic. Diabetes Obes Metab. 2025 Nov;27(11):6200-6209. doi: 10.1111/dom.70004. Epub 2025 Aug 5. PMID: 40762026; PMCID: PMC12515774.
- Eli Lilly and Company. (2025, October 30). Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance [Press release]. PR Newswire.https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2025-financial-results-highlights-rd
- NovoNordisk A/S. (2025, November 5). Financial results for the third quarter of 2025 [Press release]. Novo Nordisk Investor Relations. https://www.novonordisk.com/investors/financial-results.html
- Rodriguez PJ,Zhang V,Gratzl S, et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.JAMA Netw Open.2025;8(1):e2457349. doi:10.1001/jamanetworkopen.2024.57349
About Tradipitant
Tradipitant, licensed by Vanda from Eli Lilly and Company, is a neurokinin-1 receptor antagonist currently in clinical development for gastroparesis and GLP-1 induced nausea and vomiting. The U.S. Food and Drug Administration (FDA) is also reviewing it for motion sickness, with a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2025.
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a leading global biopharmaceutical company focused on developing and commercializing innovative therapies to address unmet medical needs and improve patient lives. For more information, visit www.vandapharma.com and follow them on X @vandapharma.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements regarding the therapeutic potential of tradipitant, its impact on patient adherence, estimates of patient discontinuation rates, the growth of the GLP-1 agonist market, Vanda's development plans, and the timeline for regulatory approval. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Key factors that could impact these statements include the ability of tradipitant to mitigate nausea and vomiting, improve patient adherence, the accuracy of market estimates, and Vanda's ability to develop and obtain approval for tradipitant. Investors are cautioned not to place undue reliance on these statements, which are qualified by the cautionary statements and risk factors detailed in Vanda's filings with the U.S. Securities and Exchange Commission.
All forward-looking statements are expressly qualified by these cautionary statements. Vanda undertakes no obligation to update or revise these statements, except as required by law.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
[emailprotected]
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
[emailprotected]
Follow us on X @vandapharma
SOURCE Vanda Pharmaceuticals Inc.
Now, let's open the floor for discussion. Do you believe that medications like Tradipitant are a necessary step in making GLP-1 agonists more accessible and effective? Or should the focus be primarily on lifestyle interventions and addressing the root causes of obesity? Share your thoughts in the comments below!
